Factor XI as a Target for New Anticoagulants

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Thrombosis is a major global health burden, with current anticoagulants like heparin and vitamin K antagonists (VKAs) carrying significant bleeding risks.
• Direct oral anticoagulants (DOACs) offer improved safety profiles but still present bleeding as a primary concern.
• Factor XI is emerging as a promising therapeutic target for anticoagulation due to evidence suggesting its inhibition reduces thrombosis without substantial bleeding.

Purpose of the Study:

• To review the scientific rationale for developing factor XI inhibitors as novel anticoagulants.
• To identify leading factor XI-directed anticoagulant agents currently in development.
• To summarize clinical trial outcomes and ongoing research for this new class of antithrombotics.

Main Methods:

• Review of existing epidemiological and animal studies on factor XI's role in thrombosis.
• Identification and analysis of factor XI inhibitors in advanced clinical development.
• Synthesis of data from completed and ongoing clinical trials evaluating factor XI inhibitors.

Main Results:

• Factor XI deficiency is linked to protection against thrombosis with minimal bleeding complications.
• Several factor XI inhibitors are progressing through clinical trials, with early data suggesting potential efficacy.
• Ongoing trials are crucial for establishing the safety and effectiveness of factor XI-directed therapies.

Conclusions:

• Factor XI inhibition presents a compelling strategy for developing safer anticoagulants.
• This next generation of antithrombotic agents holds significant promise for managing thrombosis.
• Further research and clinical trials are essential to realize the full potential of factor XI inhibitors.